Business Context and Reporting Period
Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company focused on developing therapeutics targeting the TGF-β family of proteins. The company's lead product candidate, rinvatercept (KER-065), is in development for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). Its most advanced candidate, elritercept (KER-050), is being developed for myelodysplastic syndromes (MDS) and myelofibrosis, with global rights (excluding China) licensed to Takeda Pharmaceuticals. This filing covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0.4 million | $211.2 million |
| Net Loss | $(23.7) million | $148.5 million (Income) |
| Operating Expenses | $(26.2) million | $(59.2) million |
| Cash and Cash Equivalents (End of Period) | $281.5 million | $720.5 million |
| Accumulated Deficit | $(505.5) million | $(420.3) million |
| Net Cash Used in Operating Activities | $(3.5) million | $161.2 million (Provided) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $210.9 million compared to Q1 2025. The prior year included a one-time $195.4 million license revenue recognition from the Takeda agreement and $15.9 million in service revenue. Q1 2026 revenue was minimal ($0.4 million), consisting primarily of service revenue from the Hansoh agreement.
- Profitability Shift: The company reported a net loss of $23.7 million in Q1 2026, contrasting with a net income of $148.5 million in Q1 2025. The prior year's income was driven by the Takeda license revenue and a $10.0 million development milestone payment.
- Expense Reduction: Operating expenses decreased by $33.0 million year-over-year. Research and Development (R&D) expenses dropped significantly from $48.7 million to $16.1 million, primarily due to the transition of elritercept development activities to Takeda and the deprioritization of the cibotercept program.
- Cash Position: Cash and cash equivalents decreased by approximately $440 million from the prior year period, reflecting the burn rate and the absence of the large upfront Takeda payment received in early 2025.
Guidance, Outlook, and Risks
- Clinical Outlook: Management expects to initiate a Phase 2 clinical trial of rinvatercept in DMD patients in the third quarter of 2026, with initial data expected in the first half of 2027. Engagement with regulators for an ALS Phase 2 trial is planned for the second half of 2026.
- Liquidity: As of March 31, 2026, the company held $281.5 million in cash. Management believes this is sufficient to fund operations into the first half of 2028. No additional funding is currently committed.
- Restructuring: A 45% workforce reduction announced in May 2025 was completed by December 2025, with total costs of $3.1 million recognized in the prior year. This is expected to yield annualized cost savings of approximately $17 million.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the company's dependence on Takeda and Hansoh for the commercialization of elritercept, and the need for substantial additional capital to fund future operations. The company has no products approved for commercial sale.
Investor Verification Checklist
- Verify the timeline for the initiation of the rinvatercept Phase 2 trial in DMD (targeted Q3 2026).
- Confirm the status of the elritercept Phase 3 RENEW trial and any upcoming data readouts from Takeda.
- Monitor cash burn rates to validate the runway estimate extending into the first half of 2028.
- Review the terms of the Takeda and Hansoh agreements for potential future milestone triggers and royalty obligations.
- Assess the impact of the 2025 restructuring on the company's ability to execute its clinical development plans.